Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

GuruFocus.com11-13 15:06

Total Revenue: $35.3 million in Q3, a decrease of 17% compared to the prior year. Software Revenue: $31.9 million in Q3, a 10% increase compared to the same period a year ago. Drug Discovery Revenue: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483023787?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x_J83ov.I0rk3s_sJIc6Aw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e71cc4be5b144e9220905300ce978ce0","is_english":true,"pubTime":"2024-11-13 15:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483023787","market":"us","top_or_hot":-1,"title":"Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $35.3 million in Q3, a decrease of 17% compared to the prior year.\nSoftware Revenue: $31.9 million in Q3, a 10% increase compared to the same period a year ago.\nDrug Discovery Revenue: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/schrodinger-inc-sdgr-q3-2024-070645914.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSchrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/schrodinger-inc-sdgr-q3-2024-070645914.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $35.3 million in Q3, a decrease of 17% compared to the prior year.\nSoftware Revenue: $31.9 million in Q3, a 10% increase compared to the same period a year ago.\nDrug Discovery Revenue: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/schrodinger-inc-sdgr-q3-2024-070645914.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SDGR","symbol_name":"Schrodinger Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/schrodinger-inc-sdgr-q3-2024-070645914.html","article_id":"2483023787","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x_J83ov.I0rk3s_sJIc6Aw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e71cc4be5b144e9220905300ce978ce0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483023787","pubTimestamp":1731481605,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Revenue: $35.3 million in Q3, a decrease of 17% compared to the prior year.Software Revenue: $31.9 million in Q3, a 10% increase compared to the same period a year ago.Drug Discovery Revenue: $3.4 million in Q3, significantly lower than $13.7 million in Q3 last year.Software Gross Margin: 73.4% in Q3, compared to 75.7% a year ago.Overall Gross Margin: 50% in Q3 2024, down from 56% in the same period a year ago.Operating Loss: $68.4 million in Q3, compared to a loss of $56 million in Q3 2023.Net Income: Loss of $38 million or $0.52 per share in Q3, compared to a net loss of $62 million or $0.86 per share a year ago.Cash and Marketable Securities: $398 million at the end of Q3, up from $382 million at the end of Q2.R&D Expense: $51 million in Q3, compared to $47 million in Q3 last year.Sales and Marketing Expenses: $10.3 million in Q3 2024, a 13.6% increase compared to Q3 last year.G&A Expense: $24.8 million in Q3, a 4% increase compared to Q3 2023.Operating Expenses: $86 million i","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SDGR":"Schrodinger Inc.","NVS":"诺华"},"translate_title":"Schrodinger Inc(SDGR)2024年第三季度收益看涨期权亮点：应对收入挑战和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SDGR":1,"NVS":0.9},"content_text":"Total Revenue: $35.3 million in Q3, a decrease of 17% compared to the prior year.\nSoftware Revenue: $31.9 million in Q3, a 10% increase compared to the same period a year ago.\nDrug Discovery Revenue: $3.4 million in Q3, significantly lower than $13.7 million in Q3 last year.\nSoftware Gross Margin: 73.4% in Q3, compared to 75.7% a year ago.\nOverall Gross Margin: 50% in Q3 2024, down from 56% in the same period a year ago.\nOperating Loss: $68.4 million in Q3, compared to a loss of $56 million in Q3 2023.\nNet Income: Loss of $38 million or $0.52 per share in Q3, compared to a net loss of $62 million or $0.86 per share a year ago.\nCash and Marketable Securities: $398 million at the end of Q3, up from $382 million at the end of Q2.\nR&D Expense: $51 million in Q3, compared to $47 million in Q3 last year.\nSales and Marketing Expenses: $10.3 million in Q3 2024, a 13.6% increase compared to Q3 last year.\nG&A Expense: $24.8 million in Q3, a 4% increase compared to Q3 2023.\nOperating Expenses: $86 million in Q3, compared to $80 million in Q3 last year.\n\n\nWarning! GuruFocus has detected 6 Warning Signs with SDGR.\n\nRelease Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nSchrodinger Inc (NASDAQ:SDGR) announced a significant collaboration with Novartis, which includes a $150 million upfront payment and potential for up to $2.3 billion in milestone payments.\nThe company reported a 10% increase in software revenue for Q3, driven by increased hosted revenue and customer transitions to hosted software licenses.\nSchrodinger Inc (NASDAQ:SDGR) added $48 million to its cash balance from the sale of Morphic to Lilly, bolstering its financial position.\nThe company is advancing its proprietary pipeline with three clinical stage programs, with initial data expected in 2025.\nSchrodinger Inc (NASDAQ:SDGR) has raised the lower end of its software revenue growth guidance for the year, indicating confidence in future performance.\n\n Negative Points \n\nSoftware revenue for Q3 was slightly below expectations, partly due to slower recognition of revenue from the Gates Foundation grant.\nDrug discovery revenue was significantly lower in Q3 compared to the previous year, leading to a reduction in full-year guidance for this segment.\nThe company's overall gross margin decreased to 50% in Q3, down from 56% a year ago, impacted by lower drug discovery revenue and software gross margin.\nOperating expenses increased, driven by higher R&D costs, contributing to an operating loss of $68.4 million for the quarter.\nSchrodinger Inc (NASDAQ:SDGR) reported a net loss of $38 million for Q3, although this was an improvement from the previous year's loss.\n\n Q & A Highlights \nQ: Can you expand on the key drivers that give you confidence in the updated software guidance, and how does the Novartis deal contribute to this? A: Geoff Porges, CFO, explained that the fourth quarter typically accounts for a large portion of annual revenue, around 42% to 44%. The Novartis deal is a significant component but not the only one. Discussions with multiple companies about renewals are ongoing, and the confidence in the guidance range is based on these discussions and the progress made so far in the quarter.\nQ: Should the narrowed drug discovery guidance be seen as a timing issue, and can we expect a stronger performance in early 2025? A: Geoff Porges noted that the reduction in guidance reflects timing uncertainties around year-end events. Confidence for next year is high, with expectations that opportunities anticipated for the end of this year may materialize in 2025, bolstered by the Novartis collaboration.\nQ: What percentage of your software business is now cloud-based versus on-premises? A: Geoff Porges stated that 28% of the software business was hosted in Q3, up from 23% last year. The percentage is higher when focusing solely on customer contracts, likely in the high 30% range. The trend towards hosted solutions is expected to continue over the next few years.\nQ: With initial MALT1 data expected soon, what are your expectations for this data release, and how are you defining success? A: Karen Akinsanya, President of R&D Therapeutics, mentioned that the focus is on safety, PK, PD, and early efficacy evidence. The study is a dose escalation one, not powered for full efficacy analysis, but they are looking for positive drug properties and activity evidence in relapsed refractory B-cell malignancy patients.\nQ: How are you managing P&L with advanced clinical programs, and what are the go/no-go criteria for advancing clinical programs beyond Phase 1? A: Geoff Porges emphasized focusing on reducing expense growth and achieving operating leverage. Investment continues in the platform and proprietary molecules, but not all molecules will be advanced independently. Karen Akinsanya added that monotherapy activity is crucial for MALT1, CDC7, and Wee1, with clear evidence of activity being the bar for advancement.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483023787"}